



The advantage of extended genotyping

Confidently manage your patients'
risk of cervical cancer.

BD Onclarity™ HPV Assay



Learn more




BD

Elevated clinical management

New guidelines separate HPV-positive patient management into three different risk-based tiers.³

Patient management with BD Onclarity™ (Co-Testing / HPV Primary)



Tier 1



Tier 2



Tier 3

^aDual Stain is not FDA approved for use as a triage with BD Onclarity™ HPV Assay

It's time to redefine cervical cancer screening

There are different HPV strains with varying levels of risk to disease progression.¹ Providing a more detailed HPV result can help inform which patients are at highest risk of cervical cancer.

HPV 16/18 are declining as much as




90%

in vaccinated populations²

That's why guidelines are shifting towards HPV primary screening with extended genotyping—it enables results beyond HPV 16, 18 and 45.³

Choosing a test with extended genotyping is essential.



Know your patients' cervical cancer risk



Get more individual results

Gain better risk stratification and HPV persistence monitoring by individually identifying 6 high-risk HPV genotypes.⁴⁻⁸



Optimize patient management

Help improve cancer prevention for high-risk individuals while decreasing unnecessary procedures in lower-risk cases that could cause reproductive harm.⁴⁻⁸



Boost screening rates

Help increase testing accessibility by offering a self-collection* option using a simple swab which is comparable to clinician-collected sample sensitivity.⁹

*Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.



Comprehensive HPV test results

The powerful BD Onclarity™ individually detects more high-risk genotypes.^{†,10}

Individual results for 6 high-risk HPV genotypes

16	18	45	31	51	52
✓	✓	✓	✓	✓	✓

Grouped results for 8 moderate- and lower-risk HPV genotypes

33 / 58	35 / 39 / 68	56 / 59 / 66
✓	✓	✓

Get an advantage over tests with limited genotyping, which only individually identify HPV 16 and 18.



Tier 1



Tier 2



Tier 3



Gain actionable results

BD Onclarity™ HPV Assay

Learn more at bd.com/onclarity

*Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.

†There are currently two FDA-approved HPV tests with extended genotyping with different configurations. The BD Onclarity™ HPV Assay individually identifies 6 high-risk HPV genotypes and strategically groups 3 results for 8 moderate-risk HPV genotypes.

1. National Cancer Institute. Cancer Causes and Prevention. HPV and Cancer. Accessed July 2025.
2. Wheeler CM, et al. *J Natl Cancer Inst.* 2025;117(5):924-933.
3. Massad LS, et al. *J Low Genit Tract Dis.* 2025;29(2):134-143. doi:10.1097/LGT.0000000000000865
4. Bonde JH, et al. *J Low Genit Tract Dis.* 2020;24(1):1-13.
5. Elfgren K, et al. *Am J Obstet Gynecol.* 2017;216(3):264.e1-264.e7.
6. Radley D, et al. *Hum Vaccin Immunother.* 2016;12(3):768-772.
7. Bodily J, Laimins LA. *Trends Microbiol.* 2011;19(1):33-39.
8. Stoler MH, et al. *Gynecol Oncol.* 2019;153(1):26-33.
9. Martinelli M, et al. *Microbiol Spectr.* 2024;12(3):e0287223. doi:10.1128/spectrum.02872-23
10. BD Onclarity™ HPV Assay US Package Insert [8089894].



BD, the BD logo and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates. ©2025 BD. All rights reserved. (BD-151103 4340-WW-0925 October 2025)